Trial Profile
A Multicenter, Open-label, 8 Day Treatment Study to Assess the Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to <12 Years With Asthma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2020
Price :
$35
*
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 19 Jan 2020 Status changed from recruiting to discontinued.
- 21 Oct 2019 Planned End Date changed from 28 Jan 2020 to 23 Jul 2020.
- 21 Oct 2019 Planned primary completion date changed from 28 Jan 2020 to 23 Jun 2020.